Deutsche Märkte schließen in 6 Stunden 11 Minuten

Biogen Inc. (IDP.DE)

XETRA - XETRA Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
269,70+1,35 (+0,50%)
Ab 10:58AM CET. Markt geöffnet.

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter9.610

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Michael R. McDonnell CPAExec. VP & CFO1,86MN/A1964
Ms. Susan H. Alexander Esq.Exec. VP, Chief Legal Officer & Sec.1,79MN/A1957
Mr. Christopher A. ViehbacherPres, CEO & DirectorN/AN/A1960
Ms. Robin C. KramerSr. VP & Chief Accounting OfficerN/AN/A1966
Ms. Nicole MurphyHead of Pharmaceutical Operations & TechnologyN/AN/AN/A
Mr. Michael HenckeHead of Investor RelationsN/AN/AN/A
Ms. Natacha GassenbachChief Communication Officer & Head of Corp. AffairsN/AN/AN/A
Dr. Ginger GregoryExec. VP & Chief HR OfficerN/AN/A1968
Dr. Anabella Villalobos Ph.D.Head of Biotherapeutics & Medicinal SciencesN/AN/A1959
Dr. Mahalakshmi Radhakrishnan M.D.Chief Medical Officer & Group Sr. VPN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.s ISS Governance QualityScore, Stand 1. Februar 2023, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 5, Shareholderrechte: 2, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.